The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

ASH 2018 | MSC-FFM for the treatment of pediatric and adult patients with steroid-refractory graft-versus-host disease

Jan 8, 2019

Mesenchymal stromal cells (MSCs) are multipotent progenitor cells that showed promising activity for the treatment of steroid-resistant acute graft-versus-host disease (SR aGvHD). MSCs modulate immune responses by secreting soluble factors that can modify the stimulation, proliferation and maturation of T- and B-lymphocytes, natural killer cells, and dendritic cells. Furthermore, MSCs also induce the differentiation of regulatory T cells and regulate the Th1/Th2 ratio. At present, there are several ongoing randomized trials investigating the impact of MSCs on GvHD prevention or treatment.

At the  60 th American Society of Hematology Annual Meeting & ExpositionPeter Baderfrom Hospital for Children and Adolescents; Division for Stem Cell Transplantation and Immunology, University Hospital Frankfurt, Frankfurt, Germany, presented treatment data of pediatric and adult patients with either SR GvHD (27%) or GvHD treated with MSC-Frankfurt am Main (MSC-FFM), a novel MSC manufacturing protocol characterized by high in vitropotency and near-identity of individual doses developed by Professor Bader and colleagues.

Patients and methods

  • N = 61 pediatric patients
    • Median age = 7.7 years (range, 0.5–0)
  • N = 31 adult patients
    • Median age = 42.4 years (range, 18.4–65.6)
  • Patients from 23 centers in 6 countries were included in this study
  • Severe GvHD: 37% grade III, 59% grade IV
  • Donors: MSD (n = 21, 23%), MUD (n = 56, 61%), haploidentical ( n= 14, 15%), and MMUD (n = 1, 1%)
  • Myeloablative conditioning with TBI-(treosulfan, busulfan and fludarabine) based regimen
  • 89% of patients had received immunosuppression for GvHD prophylaxis
  • Recommended dose: 4 weekly doses of 1-2M MSC/kg
  • Patients received 3 doses on average

Key findings

  • Response 28 days after MSC:
    • CR: 28%
    • PR: 54%
    • NR: 15%
  • Response at last follow-up:
    • CR: 51%
    • PR: 30%
    • NR: 17%
  • Day-28 response rates were highly predictive of long-term responsiveness
  • Six patients relapsed and died
  • Twenty-eight deaths were treatment-related
  • 6-month overall survival for children and adults: 68% and 54%, respectively
  • Adverse events: headache, nausea/vomiting were reported shortly after infusion

Professor Bader concluded that MSC-FFM is effective for the treatment of severe pediatric and adult advanced GvHD. “The very low relapse mortality may suggest that severe GvHD effectively suppresses leukemic recurrence.” A randomized trial for the treatment of SR aGvHD is planned to start in 2019.

  1. Bader P. et al.Children and adults with steroid-refractory acute graft-versus-host disease respond to treatment with the mesenchymal stroma cell preparation "MSC-Ffm": Treatment results for 92 consecutive patients. 2018 Dec 3. 60 th American Society of Hematology Annual Meeting & Exposition, San Diego, CA.